Antiangiogenic agents and late anastomotic complications

Isabelle Deshaies, David Malka, Jean Charles Soria, Christophe Massard, Rastio Bahleda, Dominique Elias

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Anticancer agents targeting circulating vascular endothelial growth factor (VEGF) (e.g., bevacizumab and aflibercept) are strong angiogenesis inhibitors. As such, they may hamper the healing process, notably in the early postoperative period. Whether antiangiogenic agents may be associated with late postoperative healing complications is less known.We reviewed three cases of patients with anastomotic complications under antiangiogenic treatment occurring more than 1 year after initial surgery and we conducted a review of the literature. We report the first case of delayed anastomotic leakage which occurred under aflibercept therapy 13 months after a bilioenteric anastomosis and two cases of delayed rectal anastomotic complications associated with bevacizumab treatment 18 and 78 months after surgery. Fifteen similar cases of late gastrointestinal anastomotic complications were found in the English literature. Antiangiogenic agents are probably not deleterious to a healed wound. However, they appear to be associated with an increased risk of complications in a subgroup of patients. According to the 18 cases reported, the main risk factors appear to be low anterior resection for rectal cancer, perioperative radiotherapy, and early postoperative leak which heals through the formation of abundant and hypervascularized granulation tissue.

Original languageEnglish
Pages (from-to)180-183
Number of pages4
JournalJournal of Surgical Oncology
Issue number2
StatePublished - 1 Feb 2010
Externally publishedYes


  • Aflibercept
  • Anastomotic complication
  • Antiangiogenic agent
  • Bevacizumab
  • Bowel perforation
  • Healing process


Dive into the research topics of 'Antiangiogenic agents and late anastomotic complications'. Together they form a unique fingerprint.

Cite this